@article{d909eaf33a4e47e2af3076758e8ad16d,
title = "Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1",
abstract = "Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.",
author = "Heslop, {H. E.} and E. Benaim and Brenner, {M. K.} and Krance, {R. A.} and Rochester, {R. J.} and Stricklin, {L. M.} and R. Billing",
note = "Funding Information: depletion with an antibody that destroys cells without regard to their activation stated This selectivity would be expected to preserve the anti-infective and antileukaemic properties of the donor graft, provided these desirable cells are not activated by the onset of GVHD. Third, the antibody is well tolerated in therapeutic doses for long periods. This study was supported in part by NIH grants CA 20180, CA 21745 (CORE) and by the American Lebanese Syrian Associated Charities (ALSAC). Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",
year = "1995",
month = sep,
day = "23",
doi = "10.1016/S0140-6736(95)91621-0",
language = "English (US)",
volume = "346",
pages = "805--806",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8978",
}